Novavax, Inc (NASDAQ:NVAX) price on Wednesday, February 05, rose 1.96% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $8.60.
A look at the stock’s price movement, the close in the last trading session was $8.44, moving within a range at $8.44 and $8.9297. The beta value (5-Year monthly) was 2.088. Turning to its 52-week performance, $23.86 and $3.53 were the 52-week high and 52-week low respectively. Overall, NVAX moved -2.82% over the past month.
Novavax, Inc’s market cap currently stands at around $1.38 billion, with investors looking forward to this quarter’s earnings report slated for in March.
Analysts have a consensus estimate of 90.92M for the company’s revenue for the quarter, with a low and high estimate of 83.3M and 103.6M respectively. The average forecast suggests down to a -68.79% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 724.08M, representing a -26.39% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that NVAX is a 50% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
16 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 6 analyst(s) rate the stock as a Hold, 10 recommend NVAX as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
NVAX’s current price about -4.21% and -2.33% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 46.58, while 7-day volatility ratio is 6.32% and 7.57% in the 30-day chart. Further, Novavax, Inc (NVAX) has a beta value of 2.91, and an average true range (ATR) of 0.62. Analysts have given the company’s stock an average 52-week price target of $22, forecast between a low of $14 and high of $25. Looking at the price targets, the low is -62.79% off current price level while to achieve the yearly target high, price needs to move -190.7%. Nonetheless, investors will most likely welcome a -155.81% jump to $22 which is the analysts’ median price.
If we refocus on Novavax, Inc (NASDAQ:NVAX), historical trading data shows that trading volumes averaged 4.04 over the past 10 days and 4.64 million over the past 3 months. The company’s latest data on shares outstanding shows there are 160.15 million shares.
The 4.52% of Novavax, Inc’s shares are in the hands of company insiders while institutional holders own 59.81% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 38.07 million on 2025-01-15, giving us a short ratio of 8.38. The data shows that as of 2025-01-15 short interest in Novavax, Inc (NVAX) stood at 2963.9998 of shares outstanding, with shares short falling to 39.16 million registered in 2024-12-13. Current price change has pushed the stock 6.97% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the NVAX stock continues to rise going into the next quarter.
